Interim Results from the Ongoing Phase II Trial of Brentuximab Vedotin in Combination with R-CHOP as Front-Line Therapy for DLBCL


Interim Results from the Ongoing Phase II Trial of Brentuximab Vedotin in Combination with R-CHOP as Front-Line Therapy for DLBCL
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Stephen M Ansell, MD, PhD (1/20/15)
Yasenchak CA et al. Brentuximab vedotin in combination with RCHOP as front-line therapy in patients with DLBCL: Interim results from a phase 2 study. Proc ASH 2014;Abstract 1745.

Dr Ansell is Professor of Medicine in the Division of Hematology at Mayo Clinic in Rochester, Minnesota.